|
|
 |
|
Viewing report
|
|
|
|
Evolving Trends in Biopharmaceutical Licensing: Deal Assessments, Drivers and Resistors
Business Insights, March 2009, Pages: 112
Large Pharma companies have become heavily dependant upon alliances and in-licensing to gain access to technologies/new molecular entities from Biopharma. This reliance has strengthened Biopharma’s bargaining position, and is reflected in negotiation tactics which aim to expand their role beyond product discovery and development towards an active participation in the the future of their products. This is emphasized by the growing complexity of licensing deals, as Biopharma attempts to secure marketing and commercialization rights within partnership deals.
Furthermore, recent increases in internal Biopharma consolidation are an indicator of the ability of well-established Biopharma companies to effectively compete against traditional big Pharma.
‘Evolving Trends in Biopharmaceutical Licensing’ is a report that provides a detailed analysis of licensing strategies in the biopharmaceutical industry over the 2001-08 period. This report examines the growth of the biopharmaceutical industry, deal-making trend data, drivers and challenges facing biopharmaceutical licensing, and profiles of biopharmaceutical licensing among leading companies. The future prospects of the industry are assessed and the potential impact of political/regulatory factors upon licensing and alliances is identified. This report also investigates the influence of the recent upsurge in M&A activity and provides recommendations on the strategies that can sustain future growth.
Key Findings
-Several top-ranked Biopharma companies have matched the consistent sales growth of major traditional pharma companies. A key component of this success has been the increasing reliance of big Pharma to improve R&D productivity and rejuvenate sales of marketed portfolios through licensing and partnership deals.
-Big Pharma has been acquiring Biopharma companies at an increasing rate, resulting in this becoming the fastest-growing M&A sector in 2008 with deal values up 87%. Intense competition and financial uncertainty has also prompted a surge in biopharma consolidation, with 52 biopharma/biopharma deals in 2007.
-Considerable potential for Biopharma licensing deals still exists, particularly within the OAD class of drugs and non-invasive insulin drug delivery technologies.
-The total deal size of early-stage alliances with biopharma has increased six-fold, with total deal values in 2007 estimated at $18bn. This has been driven by the relatively lower costs of discovery and lead development, despite the higher risk of failure.
-Co-development/co-promotion deals accounted for 30% of licensing deals over 2006-07. Licensing deals will continue to become more complex due to biopharma’s desire to remain involved in their product lifecycle beyond the stages of discovery and development
Use this report to...
- Examine the licensing landscape of the biopharma industry with this report’s analysis of Biopharma and Pharma licensing and alliance activity and an examination of specific approaches utilized by both sectors.
- Discover the drivers and challenges facing Biopharma licensing, understand how
Biopharma companies are preparing to exploit new opportunities and assess deal-making trends across clinical trials phases and key therapeutic areas.
- Evaluate the strategies of leading companies involved in biopharmaceutical licensing with this report’s analysis of deal activities amongst leading players and identify the changing dynamics of Biopharma/Pharma partnerships.
- Assess the future prospects of the Biopharma industry and how current market and political/regulatory factors will impact the dynamics of licensing and alliances, as well as potential strategies for sustaining growth.
Explore issues including...
Biopharmas reduced reliance on Pharma. Biopharma is sustaining its efforts to increase its role outside of product development/discovery to become actively engaged in the future of their products. As such, it is becoming increasingly difficult to differentiate big Pharma from major Biopharma companies.
Optimizing revenue potential. Biopharma are increasingly targeting high value therapy areas, such as oncology and inflammatory disease, bringing them into direct competition with major Pharma.
Future competitive strategies. With licensing deals increasing in value and complexity, Biopharma companies are looking to increase their involvement by forming long-term, partnership-based relationships. This active engagement in licensing deals will typically involve the negotiation of equity investment and the co-promotion and co-marketing of a drug that allows Biopharma to generate additional downstream revenues.
Drug development potential. The emergence of several new Biopharma companies with innovative technology platforms has created immense potential for intra-Biopharma licensing trends to continue developing novel drugs that can successfully differentiate themselves within the marketplace.
Discover...
- How will the increasing competition for attractive Biopharma licensing candidates affect deal terms and values?
- How can Biopharma companies improve their licensing strategies to ensure future growth?
- What have been the major trends in licensing agreements between Biopharma and Pharma over 2001-08?
- Which strategies have Biopharma used to reduce their reliance on Pharma?
- How has the value, volume and competition for Biopharma licensing deals changed over 2001-08?
- What have been the strategies of successful Biopharma and Pharma deal-makers?
- Why are Biopharma and Pharma increasingly adopting M&A strategies instead of entering into licensing agreements?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
The Top 10 Contract Research Organizations: Positioning, Performance and SWOT Analyses
|
|
|
|
